Last Updated : July 11, 2012
Details
FilesGeneric Name:
Fidaxomicin
Project Status:
Complete
Therapeutic Area:
Clostridium difficile infection
Manufacturer:
Optimer Pharmaceuticals Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Dificid
Project Line:
Reimbursement Review
Project Number:
SR0285-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
Clostridium difficile infection
Recommendation Type:
Do not list at the submitted price
Final Recommendation:
Files
Last Updated : July 11, 2012